CYP2C19 and stroke disorder: The frequencies of CYP2C19*2 and CYP2C19*17 in our study were 30.7% and 30.4%, respectively, which is much higher than what the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2C19 genotype and clopidogrel therapy in white patients indicate [22], but are in line with previous studies in patients with CVD and stroke [23, 24].